|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118157 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-02 17:52:27 |
|
注册时间: Date of Registration: |
2026-02-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
奥沙西泮与地西泮治疗酒依赖急性戒断症状的疗效与安全性比较:一项多中心实用性随机对照研究(pRCT) |
|
Public title: |
Comparison of the efficacy and safety of oxazepam and diazepam in the treatment of acute withdrawal symptoms of alcohol dependence A multicenter practical randomized controlled study (pRCT) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
奥沙西泮与地西泮治疗酒依赖急性戒断症状的疗效与安全性比较:一项多中心实用性随机对照研究(pRCT) |
|
Scientific title: |
Comparison of the efficacy and safety of oxazepam and diazepam in the treatment of acute withdrawal symptoms of alcohol dependence A multicenter practical randomized controlled study (pRCT) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王芳芳 |
研究负责人: |
郝伟 |
|
Applicant: |
Wang Fangfang |
Study leader: |
Hao Wei |
|
申请注册联系人电话: Applicant telephone: |
+86 177 0408 9454 |
研究负责人电话:
Study leader's |
+86 177 0408 9454 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1945917911@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1945917911@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南长沙人民中路139号 |
研究负责人通讯地址: |
湖南长沙人民中路139号 |
|
Applicant address: |
139 Middle of Renmin Road, changsha, Hu'nan |
Study leader's address: |
139 Middle of Renmin Road, changsha, Hu'nan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅二医院 |
||
|
Applicant's institution: |
The Second Xiangya Hospital, Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅二医院 |
||
|
Affiliation of the Leader: |
The Second Xiangya Hospital, Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LYEC2025-0325 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅二医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of the Second Xiangya Hospital, Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-24 00:00:00 | ||
|
伦理委员会联系人: |
陈老师 |
||
|
Contact Name of the ethic committee: |
Teacher Cheng |
||
|
伦理委员会联系地址: |
湖南省长沙市人民中路 139 号 |
||
|
Contact Address of the ethic committee: |
No. 139, Renmin Middle Road, Changsha City, Hunan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 8529 2476 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中南大学湘雅二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Xiangya Hospital, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南长沙人民中路139号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
139 Middle of Renmin Road, changsha, Hu'nan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖南洞庭药业 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hunan Dongting Pharmaceutical |
||||||||||||||||||||||
|
研究疾病: |
酒精戒断综合征 |
||||||||||||||||||||||
|
Target disease: |
AWS |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较奥沙西泮与地西泮在酒依赖急性戒断症状治疗中的疗效与安全性,并重点评估奥沙西泮在肝功能异常患者中的临床优势。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the efficacy and safety of oxazepam and diazepam in the treatment of acute withdrawal symptoms of alcohol dependence, and to focus on evaluating the clinical advantages of oxazepam in patients with abnormal liver function. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.住院患者;年龄18-70岁; 2.符合DSM-5酒精使用障碍诊断标准4至4条以上; 3.当前处于戒断期,CIWA-Ar评分≥16分; 4.医生评估适合苯二氮草类药物治疗; 5.签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Inpatients; Aged 18 to 70; 2. Meet four or more of the DSM-5 diagnostic criteria for alcohol use disorder; 3. Currently in the withdrawal period with a CIWA-Ar score of >=16 points; 4. The doctor assesses that benzodiazepines are suitable for treatment. 5. Sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.合并其他物质依赖(除尼古丁); 2.严重精神障碍或认知障碍影响评估; 3.妊娠或哺乳期; 4.对研究药物过敏或禁忌; 5. ALT或AST>500; 6.纽约心功能评级(NYHA)评级≥3级; 7.既往存在HIV感染、自身免疫缺陷患者; 8.无法配合随访或者研究者认为不合适。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combined with other substance dependencies (except nicotine); 2. Impact assessment of severe mental disorders or cognitive impairments; 3. Pregnancy or lactation period; 4. Allergic to or contraindicated to the investigational drug; 5. ALT or AST>500; 6. New York Cardiac Rating (NYHA) rating >= level 3; 7. Patients with a history of HIV infection or autoimmune deficiency; 8. Inability to cooperate with follow-up or deemed inappropriate by the researcher. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-04 00:00:00至 To 2026-02-04 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-02-04 00:00:00 至 To 2026-02-04 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
医生判断患者适用两种药物后,采取传统密封信封法进行随机分配(开放标签,不盲法),随机方式RANDARRAY随机排序。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
After the doctor determines that the patient is suitable for two drugs, the traditional sealed envelope method is used for random allocation (open label, non-blinding method),,Randomly sort by RANDARRAY. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
none |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
CRF |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
CRF |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |